Cohen M L, Schenck K
Department of Cardiovascular Pharmacology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285.
Life Sci. 1989;44(14):957-61. doi: 10.1016/0024-3205(89)90495-5.
Both serotonin and histamine increased cutaneous vascular permeability in rats; however, serotonin was approximately 100-fold more potent than histamine. LY53857 (0.1 and 1.0 mg/kg, i.p.), a selective 5HT2 receptor antagonist, blocked serotonin- but not histamine-induced increases in cutaneous vascular permeability. the alpha 1 receptor antagonist, prazosin, did not significantly affect increases in vascular permeability produced by serotonin. These data extend previous studies with LY53857 by further documenting its selectivity as a 5HT2 receptor antagonist. In addition, these results with a selective 5HT2 receptor antagonist provide evidence that 5HT2 receptor activation may be the predominant mechanism associated with vascular permeability changes induced by serotonin.
血清素和组胺均可增加大鼠皮肤血管通透性;然而,血清素的效力约为组胺的100倍。选择性5HT2受体拮抗剂LY53857(0.1和1.0毫克/千克,腹腔注射)可阻断血清素诱导的而非组胺诱导的皮肤血管通透性增加。α1受体拮抗剂哌唑嗪对血清素引起的血管通透性增加无显著影响。这些数据通过进一步证明LY53857作为5HT2受体拮抗剂的选择性,扩展了先前对其的研究。此外,这些使用选择性5HT2受体拮抗剂的结果表明,5HT2受体激活可能是与血清素诱导的血管通透性变化相关的主要机制。